FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
But the former is paying a fraction of what Merck shelled out for raludotatug.
Enhertu plus Perjeta shows a convincing progression-free survival benefit over a Perjeta triplet.
Gilead’s TROP2 ADC sets the bar for Astra/Daiichi’s Datroway in first-line TNBC.
BNT142 looks lacklustre, but the company still sees promise in mRNA-encoded bispecifics.
Crunch time approaches for UroGen.